Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocyticleukemia and rheumatoid arthritis.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
2
Objective: to investigated the therapy effect and prognosis related factors in the Acute Non-lymphocyticleukemia (ANLL) patients.
目的：探讨我院急性非淋巴细胞性白血病(ANLL)患者的治疗效果及其预后相关因素。
3
The plasma concentration of thrombomodulin (TM) were measured in 29 cases of acute non-lymphocyticleukemia (ANLL). Plasma TM level significantly increased in ANLL patients.